The effect of Artichoke Leaf Extract in the patients with Non Alcoholic Steatohepatitis (NASH).

The effect of Artichoke Leaf Extract on Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) in the patients with Non Alcoholic Steatohepatitis (NASH).

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014070218321N1

Enrollment

Registered

2014-08-04

Start date

2013-12-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non alcoholic steatohepatitis. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: placebo group received 6 placebo tablets daily (2 tablets after break fast ,2 tablets after lunch and 2 tablets after dinner) for 8 weeks. Intervention 2: Intervention group received 6

Placebo

Treatment - Drugs

placebo group received 6 placebo tablets daily (2 tablets after break fast ,2 tablets after lunch and 2 tablets after dinner) for 8 weeks.

Intervention group received 6 Cynarckol tablets daily, containing 2700 mg Artichoke Leaf Extract after each meal (2 tablets after break fast ,2 tablets after lunch and 2 tablets after dinner) for 8 we

Eligibility

Sex/Gender

All

Age

20 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Abnormal serum transaminases = 30 U/L ; Fatty liver in ultrasonography; At least one of the following, FBS greater than 100 mg/dL or a previous diagnosis of type II diabetes,obesity ( Body mass index of 30 or higher ),Blood pressure greater than 130/85 ,Triglyceride-levels greater than 150 mg/dl ,HDL-cholesterol lower than 40 mg/dl (men) and 50 mg/dl (women) ,Total cholesterol greater than 200 mg/dl. Exclusion criteria:Daily alcohol consumption;Type I diabetes;Concomitant liver diseases,Presence of HCV antibody or HBs antigen, auto-immune hepatitis, hemochromatosis, Wilson’s disease, alpha1 anti-trypsin deficiency, Biliary obstruction;Use of livergol,Vit E, Vit C,UDCA,Heptotoxic Drug;Treatment with a drug known to induce NASH (amiodarone,calcium channel blocker, tamoxifen), and oral anticoagulation;Decompensated cirrhosis;Serious disease limiting life expectancy;Pregnancy and lactation;people who are Allergy sensitive to the Asteraceae/Compositae family.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Alanine aminotransferase (ALT). Timepoint: before and after intervention. Method of measurement: IU/Lit.;Aspartate aminotransferas (AST). Timepoint: before and after intervention. Method of measurement: IU/Lit.	—

Secondary

Measure	Time frame
Total cholestrol. Timepoint: before and after the intervention. Method of measurement: Mg/dL.;LDL-C. Timepoint: before and after the intervention. Method of measurement: Mg/dL.;HDL-C. Timepoint: before and after the intervention. Method of measurement: Mg/dL.;Triglycerid. Timepoint: before and after the intervention. Method of measurement: Mg/dL.;Fasting blood sugar. Timepoint: before and after the intervention. Method of measurement: Mg/dL.	—

Measure

Time frame

Total cholestrol. Timepoint: before and after the intervention. Method of measurement: Mg/dL.;LDL-C. Timepoint: before and after the intervention. Method of measurement: Mg/dL.;HDL-C. Timepoint: before and after the intervention. Method of measurement: Mg/dL.;Triglycerid. Timepoint: before and after the intervention. Method of measurement: Mg/dL.;Fasting blood sugar. Timepoint: before and after the intervention. Method of measurement: Mg/dL.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactVajiheh Rangboo

Qazvin University of Medical Sciences

vrangboo@qums.ac.ir+98 28 3336 9581

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 2, 2026